To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Boehringer Ingelheim

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: BI 1026706; Drug: BI 1026706 Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01763333

1320.1

2012-002366-12 (EudraCT Number)

Details and patient eligibility

About

To investigate the safety, tolerability, pharmacokinetics and the relative bioavailability of BI 1026706

Enrollment: 80 patients

Sex: Male

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. healthy male subjects

Exclusion criteria

1. Any relevant deviation from healthy conditions

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Single Group Assignment

Masking: Single Blind

---

80 participants in 2 patient groups

1 BI 1026706 single rising dose part

Experimental group

Description:

single rising doses of BI 1026706

Treatment:

Drug: BI 1026706 Placebo

Drug: BI 1026706

2 BI 1026706 bioavailability part

Experimental group

Description:

bioavailability part of BI 1026706

Treatment:

Drug: BI 1026706